Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, ONC201, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
NCT03492138Phase 2Terminated
- Start
- Mar 2018
- Primary completion
- Jan 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dordaviprone in multiple myeloma (MM). Started Mar 2018; status: terminated.
02
Drugs
dordaviprone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03492138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03492138.